Freenome, Inc. Common stock

FRNM

NASDAQHealthcareBiotechnology

在 GoAI 中打开

常规交易时段

US$14.03

+US$0.25 · +1.81%

8月25日 11:58 ET

盘中时间采用ET。市场数据可能有所延迟。

公司概况

公司网站

Perceptive Capital Solutions Corp. is a blank check company, which engages in the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded by Joseph Eric Edelman, Adam Leo Stone, and Michael R. Altman on March 22, 2024 and is headquartered in New York, NY.

行业: Biotechnology
部门: Healthcare
总部: US
首席执行官: Aaron Elliott
上市以来: 2026年7月21日
雇员: 363

市场位置

日内区间

当前US$14.03，

US$13.695US$14.17

52周区间

当前US$14.03，

US$9.95US$14.47

开盘价: US$13.70
前收盘价: US$13.78
成交量: 23.15万; 0.95× 平均值
平均成交量: 24.26万; 日均成交量
市值: 1.14亿 USD
贝塔: 0.35; 市场参考 1
50天平均值: US$11.5576; 高于平均水平+21.39%
200天平均值: US$11.8463; 高于平均水平+18.43%

财报历史与展望

EPS：实际值与预期值

近期已公布业绩

实际值预期值

营收：实际值与预期值

近期已公布业绩

实际值预期值

分析师评级

第三方分析师预期可能变化，并非 GoAI 建议。

分析师目标价

平均目标

US$18.25

上涨空间 30.08%

过去 12 个月12个月预测最高：US$21.00平均的：US$18.25最低：US$17.00

FRNM 消息

globenewswire.com2026年8月12日

FDA Grants Breakthrough Device Designation to Freenome's Blood-Based SimpleScreen™ Lung Cancer Screening Test

BRISBANE, Calif., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Freenome, Inc. (Nasdaq: FRNM), an early cancer detection company developing blood-based screening tests, today announced that the U.S. Food and Drug Administration…

阅读源码

reuters.com2026年7月27日

FDA approves Freenome's blood test for colorectal cancer screening

The U.S. FDA has approved Freenome's blood-based colorectal cancer screening test for older adults, paving the way for partner Abbott to launch it in the U.S. this fall, ‌the companies said on Monday.

阅读源码

globenewswire.com2026年7月27日

FDA Approves Freenome's SimpleScreen™ CRC Blood-Based Screening Test; Abbott to Commercialize in the U.S.

– Approval expands colorectal cancer screening options for the up to 60 million Americans who are overdue for screening – – Medicare coverage and American Cancer Society guidance support broader access to blood-based…

阅读源码

globenewswire.com2026年7月20日

Freenome Debuts as a Publicly Traded Company Focused on Blood-Based Early Cancer Detection

– Freenome common stock expected to begin trading on the Nasdaq Capital Market under the ticker symbol "FRNM" on July 21, 2026 – – Gross proceeds to Freenome totaled more than $300 million through a PIPE, led by…

阅读源码